Summary
Boston Scientific Corporation reported a slight decrease in net sales for the second quarter and the first half of 2008, down 2% year-over-year for both periods. Net income also declined in the second quarter to $98 million from $115 million in the prior year, although it significantly increased for the first half of the year to $420 million from $235 million in 2007, largely due to significant gains from divestitures and improved operational efficiency from restructuring efforts. The company has been actively divesting non-strategic businesses, generating substantial proceeds and streamlining operations. Despite revenue challenges in its core coronary stent business due to increased competition, Boston Scientific is focusing on its two-platform drug-eluting stent strategy and new product launches in its Cardiac Rhythm Management segment, which showed positive growth. The company is also making progress in resolving its FDA quality system issues, which have impacted product launch timelines.
Financial Highlights
25 data points| Revenue | $2.02B |
| Cost of Revenue | $604.00M |
| Gross Profit | $1.42B |
| SG&A Expenses | $655.00M |
| Operating Expenses | $1.12B |
| Operating Income | $303.00M |
| Interest Expense | $118.00M |
| Net Income | $98.00M |
| EPS (Basic) | $0.07 |
| EPS (Diluted) | $0.07 |
| Shares Outstanding (Basic) | 1.50B |
| Shares Outstanding (Diluted) | 1.51B |
Key Highlights
- 1Net sales decreased by 2% for both the three and six months ended June 30, 2008, compared to the prior year.
- 2Net income for the second quarter of 2008 was $98 million, down from $115 million in Q2 2007, but first-half net income rose significantly to $420 million from $235 million.
- 3The company completed the sale of several non-strategic businesses (Auditory, Cardiac Surgery, Vascular Surgery, Fluid Management, Venous Access) and programs, generating significant proceeds.
- 4Restructuring efforts, including headcount reductions, are ongoing, aimed at aligning expenses with revenues and improving long-term shareholder value.
- 5The coronary stent business faced increased competition, leading to a decline in U.S. drug-eluting stent sales and market share, although international sales grew.
- 6Cardiac Rhythm Management (CRM) product revenue increased, driven by new product launches and favorable currency exchange rates.
- 7The company continues to address FDA regulatory issues, working towards resolving a corporate warning letter impacting product launch timelines.